Investors should monitor upcoming milestones, including the initiation of the BIM-DRS first-in-human trial in H2 2026 and four-year follow-up data from the FIH trial in Q4 2026. The strong clinical data and extended cash runway reduce near-term dilution risk and support long-term value creation if Phase 3 trials succeed.
SGP drugs
SGP drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 27 $22.61entry
- T+1 · 8mo ago +3.36%α +3.72% · $23.37
- T+5 · 8mo ago +0.18%α −3.69% · $22.65
- T+20 · 7mo ago +4.60%α −8.14% · $23.65
- T+60 · 5mo ago −12.65%α −28.72% · $19.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SpyGlass Pharma reported its Q4 and full-year 2025 financial results alongside key clinical and corporate updates, including the successful $172.5 million IPO in February 2026. The company highlighted positive 12-month Phase 1/2 data for its BIM-IOL System, showing sustained intraocular pressure control and elimination of eye drops in 97% of patients. Despite increasing R&D and G&A expenses, the IPO has extended its cash runway to fund operations through 2028.
Key Financial Metrics
Key Facts
- Raised $172.5 million in gross proceeds from IPO completed on February 9, 2026.
- 12-month Phase 1/2 trial data show 98% of patients on the 78-mcg dose of BIM-IOL System were free of IOP-lowering eye drops, with a 34% mean IOP reduction and no serious ocular adverse events.
- Cash, cash equivalents, and short-term investments totaled $107.4 million as of December 31, 2025, with post-IPO cash expected to fund operations through 2028.
- Net loss was $12.6 million for Q4 2025 ($5.72/share), up from $8.4 million ($4.58/share) in Q4 2024.
- Phase 3 trials (SGP-005 and SGP-006) for BIM-IOL System are underway, with first patients randomized in January 2026.
Financial Impact
The $172.5 million IPO significantly strengthens the balance sheet and extends cash runway to 2028, enabling full funding of Phase 3 trials and a first-in-human trial for BIM-DRS. However, net losses increased to $39.9 million in 2025 from $29.2 million in 2024 due to higher R&D and G&A spending.
Risk Factors
- Clinical trial delays or adverse results in ongoing Phase 3 studies could negatively impact valuation.
- As a pre-revenue biopharma company, SpyGlass Pharma remains dependent on successful clinical development and regulatory approval.
- Increased operating losses may continue as R&D and commercial preparation costs rise.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263396 |
Track record
9 reports on SGP
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +33.66% at T+20 after the Oct 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 No price data
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $33.32 Now $32.24 −3.24% settles Dec 11
- Oct 19, 202628d ago 8-K Bullish 6/10 Entry $26.16 Now $32.24 +23.24% settles Nov 17
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $24.60 to $32.88 Now $32.24 +31.06% ▲ +33.66% +37.12% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
- Oct 1, 20266w ago Press Release Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
- May 14, 202626w ago 8-K Neutral 4/10 Entry $23.21 to $18.44 Now $32.24 +38.91% ▼ −20.55% −22.67% vs SPY
- Mar 26, 202633w ago Press Release Bullish 8/10 Viewing Entry $22.61 to $23.65 Now $32.24 +42.59% ▲ +4.60% −8.14% vs SPY
- Mar 9, 202636w ago Press Release Bullish 8/10 Entry $27.12 to $21.07 Now $32.24 +18.88% ▼ −22.31% −19.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers